Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J’s Problems, Pfizer’s Options And Switch Outlook Top “The Tan Sheet” Topics In 2011

This article was originally published in The Tan Sheet

Executive Summary

Readers of “The Tan Sheet” in 2011 showed the most interest in stories about Johnson & Johnson’s OTC quality issues, Pfizer’s consumer business maneuvers and Rx-to-OTC switch outlooks. Other hot topics included omega-3 drug development, supplement GMP strategies and state pseudoephedrine laws.


Related Content

Suit Alleges Potential Cancer Link Scared J&J Away From Listerine Marketing Deal
J&J Directors Find Root Causes But Little Blame For OTC Quality Issues
Pfizer Consumer Chief Sees Chronic Conditions In OTC Future
State Pseudoephedrine Legislation
CDER Director Sees Behind-The-Counter Switches As Best Bet
J&J Separates U.S. OTCs In "Unorthodox" Reorg To Get McNeil Back On Track
OTC Pseudoephedrine Purchases In Arkansas Require In-State Identification
Pfizer's OTC, Nutritional Businesses Could Be Looking For A New Home
FDA Enforces Consent Decree Over J&J/McNeil's OTC Manufacturing
Will The Rising Tide Of Rx Omega-3s Float The Fish Oil Supplement Market?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts